Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.

Julien Edeline,Stéphane Cattan,Philippe Merle,Bruno Daniele,Stephen L. Chan,Thomas Yau,Mohamed Bouattour,Ho Yeong Lim,Yee Chao,Jennifer J. Knox,Sadahisa Ogasawara,Marcelo Garrido,Ann-Lii Cheng,Andrew X. Zhu,Richard S. Finn,Abby B. Siegel,Ahmadur Rahman,Chih-Chin Liu,Masatoshi Kudo

Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.

2021

Julien Edeline
Stéphane Cattan
Philippe Merle
Bruno Daniele
Stephen L. Chan
Thomas Yau
Mohamed Bouattour
Ho Yeong Lim
Yee Chao
Jennifer J. Knox
Sadahisa Ogasawara
Marcelo Garrido
Ann-Lii Cheng
Andrew X. Zhu
Richard S. Finn
Abby B. Siegel
Ahmadur Rahman
Chih-Chin Liu
Masatoshi Kudo

318Background: Studies have shown that OR is prognostic of OS in pts with HCC. KEYNOTE (KN)-224 (NCT02702414) evaluated pembrolizumab (pembro; anti-PD-1) in sorafenib (sora)-treated pts with aHCC a...

Keywords:

Internal medicine
Medicine
Oncology
Post-hoc analysis
overall survival
Sorafenib
landmark analysis
Pembrolizumab
previously treated
Hepatocellular carcinoma
objective response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations